FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | () - | | | | | | | | |
|--|-------|--|------------|---|---|---|---------------------------|---|---|---|--|
| Yelensky Roman | | Date of Event Requiring Stater Month/Day/Yea 19/27/2018 | nent | 3. Issuer Name and Ticker or Trading Symbol Gritstone Oncology, Inc. [GRTS] | | | | | | | |
| .ast) (First) (Middle) | | | | Relationship of Reporting Perso (Check all applicable) Director | | on(s) to Issue | | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | | |
| 5858 HORTON STREET, SUITE 210 | | | | X | Officer (give title below) See Remark | Other (specify below) ks | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | |
| (Street) EMERYVILLE CA 94608 | | | | | | | | | | | |
| | | | | | | | | Form filed by More than One Reporting Person | | | |
| (City) (State) | (Zip) | | | | | | | | | | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | | | | | |
| 1. Title of Security (Instr. 4) | | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | | |
| Common Stock | | | | | 143,224 | D | | | | | |
| | (e.ç | | | | urities Beneficially options, convertible | | s) | | | | |
| 1. Title of Derivative Security (Instr. 4) | | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securit Underlying Derivative Securit | | | 4. Convers or Exerc | cise Fo | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | |
| | | Date Expiration Date | | n Title | | Amount or Number of Shares | | ve or | | | |
| Stock Option (Right to Buy) | | 03/01/2018 ⁽¹⁾ | 02/07/2027 | 7 | Common Stock | 50,724 | 0.76 | 5 | D | | |
| Stock Option (Right to Buy) | | 10/27/2018 ⁽²⁾ | 08/06/2028 | 3 | Common Stock | 72,463 | 9.6 | | D | | |

Explanation of Responses:

- 1. The stock option vests and becomes exercisable with respect to 25% of the total number of shares on March 1, 2018. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months.
- $2. \ The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on September 27, 2018.$

Remarks:

Executive Vice President, Chief Technology Officer

<u>Dana B. Johnson, Attorney-in-</u> <u>Fact for Roman Yelensky</u> <u>09/27/2018</u>

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Gritstone Oncology, Inc. Power of Attorney

Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of Gritstone Oncology, Inc., a Delaware corporation (the "*Company*"), who is currently Andrew Allen, (ii) the Company's Chief Financial Officer, who is currently Jean-Marc Bellemin, (iii) the Company's General Counsel, or (iv) the Company's Associate General Counsel and Chief Compliance Counsel, who is currently Dana Johnson, and their respective successors (including anyone serving in such capacities on an interim or acting basis), signing singly, with full powers of substitution, as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of the Company, Forms 3, 4, and 5 and any amendments thereto in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of September, 2018.

/s/ Roman Yelensky
Roman Yelensky, Ph.D.